Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. uri icon

authors

  • Banerjee, Susana
  • Leary, Alexandra
  • Sonke, Gabe S
  • Gourley, Charlie
  • Oza, Amit
  • González-Martín, Antonio
  • Aghajanian, Carol
  • Bradley, William H
  • Holmes, Eileen
  • Lowe, Elizabeth S
  • DiSilvestro, Paul
  • Moore, Kathleen N
  • Colombo, Nicoletta
  • Scambia, Giovanni
  • Kim, Byoung-Gie
  • Oaknin, Ana
  • Friedlander, Michael
  • Lisyanskaya, Alla
  • Floquet, Anne

publication date

  • January 1, 2021